The Calcium Clue in ME/CFS

A Breakthrough Decades in the Making

For as long as most patients can remember, myalgic encephalomyelitis/chronic fatigue syndrome has been one of medicine's most contested diagnoses. Affecting an estimated 240,000 Australians alone — and millions more worldwide — ME/CFS has long been caught in a damaging limbo: too complex to pin down with a simple test, too frequently dismissed as a psychological complaint. Patients have been sent home with advice to exercise more, think differently, or simply push through. Now, researchers at Griffith University's National Centre for Neuroimmunology and Emerging Diseases (NCNED) in Queensland, Australia have produced findings that may finally, decisively shift that conversation.

The core discovery centres on calcium ion channels — proteins embedded in cell membranes that control how calcium enters a cell. In people with ME/CFS, these channels appear to function abnormally, allowing calcium ions to enter affected cells at reduced levels. That might sound like a narrow biochemical detail, but its consequences ripple outward dramatically. Calcium signalling is involved in an enormous range of cellular processes: gene expression, immune response, nervous system function, cardiovascular regulation. When that signalling is disrupted across cells in multiple systems simultaneously, the result is exactly the kind of wide-ranging, unpredictable and shifting symptom profile that has made ME/CFS so difficult to characterise — and so easy, wrongly, to attribute to psychological causes.

What the Science Actually Shows

Professor Don Staines, a clinical professor at Griffith University and a leading figure at the NCNED, has described the findings as a watershed moment in ME/CFS research — and it is not hard to see why. What the team has established is that calcium ion channel impairment is a measurable, biological feature of the illness. This places ME/CFS firmly in the category of pathological disease: one driven by a real, documentable physical mechanism, not by a patient's mindset or motivation.

The breadth of that mechanism helps explain why ME/CFS presents so differently from person to person. Because calcium-dependent cells exist across the neurological, cardiovascular and immune systems, disruption to their function can manifest as post-exertional malaise (the severe worsening of symptoms after even mild exertion), unrefreshing sleep, brain fog, orthostatic intolerance, pain, and immune dysregulation — sometimes all at once, sometimes in shifting combinations. The relapsing-remitting nature of the illness, so often used to cast doubt on its legitimacy, is entirely consistent with a biological mechanism of this kind.

The NCNED, housed at Griffith University on the Gold Coast, has been building this body of work over many years, drawing on the emerging field of neuroimmunology — the study of how the nervous system and immune system interact. This discovery represents a convergence of those threads into something clinically actionable.

The Path Toward a Diagnostic Test — and Beyond

One of the most practically significant implications of this research is its potential to underpin a definitive diagnostic biomarker. Currently, ME/CFS has no validated biological test. Diagnosis is made clinically, by ruling out other conditions and matching a patient's history to established criteria — a process that can take years and that too often ends in misdiagnosis or outright disbelief. The absence of a measurable marker has historically allowed the illness to be framed as medically unexplained, a framing that has cost patients enormously in terms of appropriate care, workplace accommodations, disability recognition and research funding.

That could change. Professor Staines has indicated that while further development work is required before a validated diagnostic test is ready for clinical use, the biological marker now exists to build one around. That is a qualitatively different situation from where the field stood even a few years ago. A blood test or similar objective measure that confirms ME/CFS would not only improve the diagnostic journey for newly ill patients — it would lend weight to the countless individuals already living with the condition who have struggled to have their illness taken seriously.

Alongside diagnostic development, candidate drug compounds are being screened in laboratory settings with an eye toward future clinical trials. This is early-stage work, and it would be premature to speak of treatments as imminent — but the existence of a confirmed biological mechanism makes a rational drug-development pipeline possible in a way it simply was not before. Researchers can now ask: what compounds might correct, or compensate for, impaired calcium ion channel function? That is a tractable scientific question. "We don't know yet if this illness is psychosomatic" is not.

What This Means for Patients — In Their Own Words

Lyn, President of the ME/CFS/FM Support Association Queensland and a person living with ME/CFS herself, described the breakthrough plainly: it is, she said, "nothing short of wonderful." Her clearest hope is not an abstract one. She wants more clinicians to take patients seriously — to stop defaulting to exercise referrals or cognitive behavioural therapy (CBT) built on the assumption that the illness is rooted in psychology rather than biology.

The distinction she draws is precise and important: ME/CFS is not psychological, she emphasises, and it is not merely physiological in some vague, unverifiable sense. It is pathological — caused by a measurable disease process. That word carries decades of weight for a community that has been told, repeatedly and often by the very professionals meant to help them, that their suffering is a product of deconditioning, anxiety, or catastrophising.

The stigma attached to ME/CFS has had real consequences. Patients have been denied benefits, lost jobs, been discharged from care and, in some cases, had their children investigated by social services when they were too ill to attend school. Research into the condition has been chronically underfunded relative to its prevalence and severity. Organisations like the NCNED, alongside patient advocacy groups, community forums such as Phoenix Rising and Health Rising, and researchers and journalists who have followed the science closely, have spent years arguing that the biology would eventually bear out what patients already knew: this illness is real, it is serious, and it demands a serious scientific response.

This finding does not end that work. But it changes its footing. With a confirmed biological mechanism, the field can move from defending the existence of the illness to building treatments worthy of it — and patients, at last, have science that speaks clearly on their behalf.